Modern Clinical Research on LSD by Liechti, Matthias E.
OPEN
Review
Modern Clinical Research on LSD
Matthias E Liechti*,1,2,3
1Psychopharmacology Research, Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, University of Basel,
Basel, Switzerland; 2Psychopharmacology Research, Clinical Pharmacology and Toxicology, Department of Clinical Research, University Hospital
Basel, University of Basel, Basel, Switzerland; 3Psychopharmacology Research, Clinical Pharmacology and Toxicology, Department of Internal
Medicine, University Hospital Basel, University of Basel, Basel, Switzerland
All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are
reviewed herein. There were five recent studies in healthy participants and one in patients. In a controlled setting, LSD acutely induced bliss,
audiovisual synesthesia, altered meaning of perceptions, derealization, depersonalization, and mystical experiences. These subjective effects of
LSD were mediated by the 5-HT2A receptor. LSD increased feelings of closeness to others, openness, trust, and suggestibility. LSD impaired
the recognition of sad and fearful faces, reduced left amygdala reactivity to fearful faces, and enhanced emotional empathy. LSD increased the
emotional response to music and the meaning of music. LSD acutely produced deficits in sensorimotor gating, similar to observations in
schizophrenia. LSD had weak autonomic stimulant effects and elevated plasma cortisol, prolactin, and oxytocin levels. Resting-state functional
magnetic resonance studies showed that LSD acutely reduced the integrity of functional brain networks and increased connectivity between
networks that normally are more dissociated. LSD increased functional thalamocortical connectivity and functional connectivity of the primary
visual cortex with other brain areas. The latter effect was correlated with subjective hallucinations. LSD acutely induced global increases in
brain entropy that were associated with greater trait openness 14 days later. In patients with anxiety associated with life-threatening disease,
anxiety was reduced for 2 months after two doses of LSD. In medical settings, no complications of LSD administration were observed. These
data should contribute to further investigations of the therapeutic potential of LSD in psychiatry.
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INTRODUCTION
The present article reviews studies on the clinical pharma-
cology and use of lysergic acid diethylamide (LSD) in
psychiatry research, with a focus on recent clinical studies.
Older studies that were published in the 1950s–1970s before
the prohibition of LSD are summarized elsewhere (Passie
et al, 2008). All modern controlled clinical studies of LSD
published in the past 25 years were included in the present
review based on medline and clinicaltrials.gov database
searches. Other authors have reviewed serotonergic halluci-
nogens, including LSD (Dos Santos et al, 2016; Nichols, 2016;
Passie et al, 2008), but did not cover the recent experimental
clinical LSD research.
HISTORY
LSD was first synthesized in 1938, and its psychoactive
properties were discovered in 1943. The similarity between
the subjective psychotomimetic effects of LSD and
schizophrenia were noted in 1947, leading to the experi-
mental use of LSD to model psychosis. From 1949 to 1966,
LSD (Delysid, LSD 25) was provided to psychiatrists and
researchers ‘to gain insights into the world of mental
patients’ and to assist psychotherapy. In the 1950s–1960s,
LSD and LSD-associated psychotherapy were investigated
with regard to anxiety associated with terminal cancer,
alcoholism, opioid use disorder, and depression (Passie et al,
2008). LSD is a well-studied pharmacological substance, with
more than 1000 published reports (Nichols, 2016). LSD has
been an important tool in neuroscience and drug develop-
ment (Nichols, 2016) and has influenced the arts and society.
Clinical research on LSD came to a halt in the early 1970s
because of political pressure following its widespread
uncontrolled use. Nevertheless, the recreational use of LSD
has remained high. In 2010, an estimated 32 million US
residents reported lifetime use of LSD (Krebs and Johansen,
2013). In the 1990s, clinical hallucinogen research very
slowly began again with experimental studies of psilocybin
and dimethyltryptamine (DMT) (Gouzoulis-Mayfrank et al,
2005; Strassman and Qualls, 1994a; Strassman et al, 1994b).
The first modern research findings from studies of LSD
(Gasser et al, 2014, 2015), psilocybin (Carhart-Harris et al,
2016a; Griffiths et al, 2016; Grob et al, 2011; Johnson et al,
2014; Ross et al, 2016), and ayahuasca (which contains
DMT) (Osorio et al, 2015) in psychiatric patients have only
very recently been published. Legally authorized LSD-
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assisted psychotherapy is currently offered to very few
patients in Switzerland in the context of compassionate use
and based on case-by-case authorizations by the Federal
Health Office. In addition, experimental research on LSD in
healthy subjects has gained new momentum and resulted in
novel findings, which are reviewed herein.
RECEPTOR INTERACTION PROFILE AND MECHAN-
ISM OF ACTION
Serotonergic hallucinogens can be classified based on their
chemical structure as phenethylamines and tryptamines.
Within the tryptamines, there are the simple tryptamines
including the classic natural hallucinogens psilocybin (the
prodrug for psilocin), DMT, and mescaline and the ergolines
including mainly LSD. Table 1 shows the human receptor
interaction profile for LSD compared with that of other
classic serotonergic hallucinogens obtained with the same
assays (Table 1). LSD potently binds to human serotonin
(5-hydroxytryptamine (5-HT)) 5-HT1A, 5-HT2A, 5-HT2C,
dopamine D2, and α2 adrenergic receptors and less potently
to α1 adrenergic, D1, and D3 receptors (Rickli et al, 2015,
2016) (Table 1). LSD also activates rat and mouse trace
amine-associated receptor 1 (TAAR1) but not human TAAR1
(Simmler et al, 2016). LSD is a partial agonist at
5-HT2A receptors (Rickli et al, 2016) (Table 1). 5-HT2A
receptors primarily mediate the hallucinogenic effects of LSD
(Nichols, 2016; Preller et al, 2017; Vollenweider et al, 1998;
Kraehenmann et al, 2017). The affinity of hallucinogens for
5-HT2A receptors but not 5-HT1A receptors is correlated with
psychoactive potency in humans. Although the subjective
effects of LSD in humans can be blocked by pretreatment
with a 5-HT2A receptor antagonist (Preller et al, 2017;
Kraehenmann et al, 2017) and are therefore clearly mediated
by 5-HT2A receptor activation, the signaling pathways and
downstream effects that mediate the effects of LSD have not
been conclusively identified (Nichols, 2016). A key mechan-
ism of action of LSD and other serotonergic hallucinogens is
the activation of frontal cortex glutamate transmission
secondary to 5-HT2A receptor stimulation. However, inter-
actions between the 5-HT and glutamate systems are unclear
(Nichols, 2016). Increases in glutamatergic activity in the
prefrontal cortex may result in downstream modulatory
effects in subcortical areas and alterations in the gating
functions of sensory and cognitive processing. Some notable
differences can be seen between the pharmacological profiles
of LSD and other serotonergic hallucinogens. First, LSD
more potently binds 5-HT2A receptors than psilocybin,
mescaline, and DMT (Rickli et al, 2016) (Table 1). Second,
LSD is more potent at 5-HT1 receptors (Rickli et al, 2016),
which may contribute to the effects of hallucinogens.
However, there are no studies on the role of the 5-HT1
Table 1 Receptor Interaction Profiles for LSD and Other Classic Serotonergic Hallucinogens at Human Receptors
LSDa Psilocinb DMTb Mescalinea
5-HT1A Receptor binding Ki± SD (μM) 0.003± 0.0005 0.123± 0.02 0.075± 0.02 4.6± 0.4
5-HT2A Receptor binding Ki± SD (μM) 0.004± 0.001 0.049± 0.01 0.237± 0.04 6.3± 1.8
5-HT2A Activation potency EC50± SD (μM) 0.261± 0.15 0.721± 0.55 0.076± 0.03 10± 1.8
5-HT2A Activation efficacy % maximum± SD 28± 10 16± 8 40± 11 56± 15
5-HT2B Activation potency EC50± SD (μM) 12± 0.4 420 3.4± 3.2 420
5-HT2B Activation efficacy % maximum± SD 71± 31 19± 6
5-HT2C Receptor binding Ki± SD (μM) 0.015± 0.003 0.094± 0.009 0.424± 0.15 17± 2.0
α2A Receptor binding Ki± SD (μM) 0.67± 0.18 6.7± 1.1 1.3± 0.2 415
α1A Receptor binding Ki± SD (μM) 0.012± 0.002 2.1± 0.01 2.1± 0.4 1.4± 0.2
D1 Receptor binding Ki± SD (μM) 0.31± 0.09 414 6.0± 0.9 414
D2 Receptor binding Ki± SD (μM) 0.025± 0.0004 3.7± 0.6 3.0± 0.4 410
D3 Receptor binding Ki± SD (μM) 0.10± 0.01 8.9± 0.8 6.3± 2.1 417
H1 Receptor binding Ki± SD (μM) 1.1± 0.2 1.6± 0.2 0.22± 0.03 425
TAAR1
c Activation potency EC50± SD (μM) 420 430 410 410
NET Receptor binding Ki± SD (μM) 430 13± 1.7 6.5± 1.3 430
NET Inhibition potency IC50 (μM) (95% CI) 4100 14 (10–19) 3.9 (2.8–5.3) 4100
DAT Receptor binding Ki± SD (μM) 430 430 22± 3.9 430
DAT Inhibition potency IC50 (μM) (95% CI) 4100 4100 52 (37–72) 4100
SERT Receptor binding Ki± SD (μM) 430 6.0± 0.3 6.0± 0.6 430
SERT Inhibition potency IC50 (μM) (95% CI) 4100 3.9 (3.1–4.8) 3.1 (2.4–4.0) 4100
Dosed Mg 0.1 12 40 300
Abbreviations: DAT, dopamine transporter; NET, norepinephrine transporter; SERT, serotonin transporter.
All data were generated using the same assays across substances to allow for direct comparisons.
aRickli et al, 2015.
bRickli et al, 2016.
cSimmler et al, 2016.
dEstimated average psychoactive dose in humans from Passie et al, 2008 and Nichols, 2004.
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receptor in the effects of LSD in humans. Third, LSD binds
adrenergic and dopaminergic receptors at submicromolar
concentrations, which is not the case for other classic
serotonergic hallucinogens (Rickli et al, 2016) (Table 1). In
animals, dopamine D2 receptors were shown to contribute to
the discriminative stimulus effects of LSD in the late phase of
the acute response (Marona-Lewicka and Nichols, 2007). In
humans, LSD may indirectly enhance dopamine neurotrans-
mission (Nichols, 2016), with no role of direct D2 receptor
stimulation (Preller et al, 2017; Kraehenmann et al, 2017).
Serotonergic hallucinogens presumably produce overall
similar acute subjective (Hollister and Hartman, 1962;
Wolbach et al, 1962) and potential therapeutic effects in
humans. The early clinical trials used mostly LSD while most
of the recent hallucinogen studies used psilocybin because of
its ease of use due to the shorter action and less controversial
history (Nichols et al, 2017; Nutt, 2016). However, modern
studies need to directly investigate whether the effects of LSD
in humans differ qualitatively from those of psilocybin and
DMT, notwithstanding LSD’s longer duration of action.
STUDIES IN HEALTHY SUBJECTS
Five novel experimental placebo-controlled studies have been
conducted in Basel, London, and Zurich in a total of 95
normal subjects (Table 2). All studies used a crossover design
and were placebo-controlled. The Basel and Zurich studies
were randomized and double-blind, whereas the London
studies were non-randomized and single-blind. Low–moder-
ate doses of LSD base of 40–80 μg intravenously (London) or
100 μg orally (Basel and Zurich) were used in studies
including brain imaging and a relatively high dose of 200 μg
LSD base was used in one study in Basel without brain
imaging. A full LSD reaction is expected at doses of
100–200 μg (Pahnke et al, 1969; Passie et al, 2008). Similar
and higher doses of LSD were used in patients in the
1950s–1970s (Krebs and Johansen, 2012; Pahnke et al, 1970).
Subjective Effects
Modern placebo-controlled studies using validated psycho-
metric scales have only recently been conducted (Carhart-
Harris et al, 2016b; Kraehenmann et al, 2017; Preller et al,
2017; Schmid et al, 2015). In a controlled setting, the
subjective effects of LSD were predominantly positive
(Dolder et al, 2016; Schmid et al, 2015). Mean group ratings
of ‘good drug effect’ and ‘drug liking’ on visual analog scales
(VASs) reached 90% of maximal possible VAS scores after
administration of 200 μg LSD (Schmid et al, 2015). In
contrast, LSD produced only small (o25%) mean group
increases in ‘negative drug effect’ and ‘fear’ (Dolder et al,
2017; Schmid et al, 2015). However, transiently greater
ratings of negative drug effects (450%) are seen in
approximately half of the subjects at a 200 μg dose of LSD
(Dolder et al, 2017). Thus, within a session all subjects
experience positive drug effects but some also negative drug
effects. Profound anxiety or panic was not experienced, and
pharmacological sedation was not needed (Dolder et al, 2016;
Schmid et al, 2015). LSD increased ratings on all dimensions
and subscales of the 5-dimension altered states of conscious-
ness (5D-ASC) scale that has been used in all modern studies
(Carhart-Harris et al, 2016b; Kraehenmann et al, 2017;
Liechti et al, 2017; Preller et al, 2017; Schmid et al, 2015)
(Figure 1). LSD mainly induced a blissful state, audiovisual
synesthesia, changes in the meaning of perceptions, and
positively experienced derealization and depersonalization
(Carhart-Harris et al, 2016b; Liechti et al, 2017; Schmid et al,
2015). An oral dose of 200 μg LSD produced significantly
greater bliss, changes in the meaning of perceptions, and
insightfulness compared with 100 μg (Liechti et al, 2017).
Intravenous LSD at a dose of 75 μg (Carhart-Harris et al,
2016b) produced similar ratings on the 5D-ASC as an oral
dose of 100 μg (Liechti et al, 2017) but lower ratings
compared with an oral dose of 200 μg (Schmid et al, 2015)
(Figure 1). Pretreatment with the 5-HT2A receptor antagonist
ketanserin fully prevented the effects of 100 μg LSD on the
5D-ASC (Kraehenmann et al, 2017; Preller et al, 2017),
indicating that the mind-altering effects of LSD in humans
are primarily mediated by 5-HT2A receptors. LSD elicited
spontaneous synesthesia-like experiences (Carhart-Harris
et al, 2016b; Liechti et al, 2017; Preller et al, 2017; Schmid
et al, 2015), but it did not induce more vivid color
experiences in response to grapheme or sound stimuli
(Terhune et al, 2016). These findings indicate that LSD alters
spontaneous processes rather than induced responses
(Terhune et al, 2016). LSD at 40–80 μg, i.v., increased
suggestibility (vividness of imagination) but not cued
imagery (Carhart-Harris et al, 2015). LSD at 200 μg, p.o.
acutely induced mystical experiences in healthy subjects and
patients during LSD-assisted psychotherapy (Liechti et al,
2017). Studies of psilocybin showed that greater acute
mystical experiences were significantly associated with
positive long-term effects on mood and personality in
healthy subjects (Griffiths et al, 2011) and better therapeutic
outcomes in patients with anxiety, depression, and substance
use disorder (Garcia-Romeu et al, 2015; Griffiths et al, 2011,
2016; Ross et al, 2016). Thus, acute substance-induced
mystical-type effects during therapeutic sessions appear to
predict the long-term effects of hallucinogens. However,
LSD-induced mystical-type effects were highly correlated
with other alterations of consciousness and particularly the
blissful state on the 5D-ASC (Liechti et al, 2017), indicating
that greater positive acute responses to hallucinogens and not
specifically mystical-type effects may generally be associated
with any better long-term effects on mood. Furthermore,
LSD increased feelings of well-being, happiness, closeness
to others, openness, and trust (Dolder et al, 2016;
Schmid et al, 2015). Such empathogenic effects on mood are
typically produced by 3,4-methylenedioxymethamphetamine
(MDMA; ecstasy) (Hysek et al, 2014a) and may facilitate
psychotherapy. A 200 μg dose of LSD produced greater
feelings of closeness to others, happiness, openness, and trust
than a 100 μg dose (Dolder et al, 2016). Consistently, an LSD
dose of 200 μg is currently used in LSD-assisted psychother-
apy in Switzerland (Gasser et al, 2014, 2015).
No differences in subjective VAS-rated responses to LSD
were found between subjects with no prior hallucinogen use
and subjects with moderate experience (1–3 prior uses)
(Schmid et al, 2015). The effects of LSD on the 5D-ASC were
also similar between subjects with no prior hallucinogen use
(n= 21) (Dolder et al, 2016) and subjects who had used LSD
14± 18 times (mean± SD) (Carhart-Harris et al, 2016b). No
correlations were found between past LSD use and the acute
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Table 2 Modern Clinical Placebo-Controlled LSD Studies
Publications related to
the study
Outcome measures Findings (LSD vs placebo)
Studies in healthy subjects
Basel, Switzerland; n= 16, dose: 200 μg p.o.; randomized, double-blind; age: 29 (25–51) years; three had previous LSD use 1–2x; NCT01878942a
Schmid et al, 2015 5D-ASC Alterations in consciousness
Schmid et al, 2015, Dolder
et al, 2016
AMRS Subjective effects
Schmid et al, 2015 ARCI Subjective effects
Schmid et al, 2015 VAS Subjective effect-time curves
Schmid et al, 2015 Investigator-rated drug effects Distance from reality, happiness, no paranoid
thinking
Schmid et al, 2015 Plasma hormone
concentrations
Increased cortisol, prolactin, oxytocin, epinephrine
Schmid et al, 2015 Acoustic startle Disruption of prepulse inhibition (PPI)
Schmid et al, 2015; Dolder
et al, 2015b, 2017
Autonomic effects Increased blood pressure, heart rate, body
temperature, and pupil diameter
Schmid et al, 2015 List of complaints Acute and subacute adverse effects
Strajhar et al, 2016 Plasma steroid concentrations Increased cortisol, cortisone, corticosterone,
11-dehydrocorticosterone, DHEA, androstendione
Dolder et al, 2016 FERT Decreased recognition of fearful faces
Dolder et al, 2016 MET Increased emotional empathy, decreased cognitive
empathy
Dolder et al, 2016 SVO Increased prosociality
Dolder et al, 2015a, b,
2017; Steuer et al, 2016
Plasma pharmacokinetics Plasma concentration-time curves of LSD,
Oxo-OH-LSD, HO-LSD, nor-LSD; Cmax, Tmax, t1/2,
AUC, and clearance values of LSD
Dolder et al, 2015a, b Urine pharmacokinetics Urinary recovery of LSD and O-H-LSD
Liechti et al, 2017 MEQ Induction of mystical-type experiences
Basel, Switzerland; n= 24, dose: 100 μg p.o.; randomized, double-blind; age: 33 (25–60) years; 3 had previous LSD use 1x; NCT02308969a
Liechti et al, 2017 5D-ASC Alterations in consciousness and dose response
Dolder et al, 2016 AMRS Subjective effects and dose response
Dolder et al, 2016 VAS Subjective effect-time curves and dose response
Dolder et al, 2016 FERT Decreased recognition of fearful and sad faces
Dolder et al, 2016 MET Trend-increase in emotional empathy, decreased
cognitive empathy
Dolder et al, 2016 SVO Prosocial orientation increased
Dolder et al, 2016, 2017 Autonomic effects Increased blood pressure, heart rate, body
temperature, and pupil diameter
Mueller et al, 2017a BOLD response to fearful faces
(n= 20)
Reduced left amygdala reactivity
Mueller et al, 2017b rsfMRI (n= 20) Increased thalamocortical connectivity
Schmidt et al, 2017 BOLD response during GO/
NO-Go (n= 18)
Impaired inhibitory performance and altered
parahippocampal activation
London, UK; n= 10, Dose 40–80 μg i.v.; non-randomized, single-blind; age 34 (26–47) years; mean previous LSD use: 65x (0–250x)
Carhart-Harris et al, 2015 CIS Increased vividness/realism of imagination
Carhart-Harris et al, 2015 MIT No change in vividness of mental imagery
Kaelen et al, 2015 Geneva emotional music scale Increased emotional response to music
Terhune et al, 2016 Grapheme/sound-color
associations
No effect on synesthesia in response to stimuli
London, UK; n= 20; dose 75 μg i.v.; non-randomized, single-blind; age 31 (22–47) years, mean previous LSD use: 14x (0–70x)
Carhart-Harris et al, 2016b 5D-ASC Alterations in consciousness
Carhart-Harris et al, 2016b PSI Cognitive disorganization, delusion, paranoia
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effects of LSD on functional magnetic resonance imaging
(fMRI) study outcomes across subjects with prior LSD use
(Speth et al, 2016; Tagliazucchi et al, 2016).
Music has typically been used in substance-assisted
psychotherapy (Gasser et al, 2014, 2015; Johnson et al,
2008). Several modern studies assessed the interactive effects
of LSD and listening to music. LSD enhanced the emotional
response to music and produced greater feelings of wonder
and transcendence compared with listening to music after
placebo (Kaelen et al, 2015). LSD increased eyes-closed
imagery or seeing scenes from the past, but listening to music
did not interact with these subjective effects of LSD on
imagery (Kaelen et al, 2016). Other researchers found that
LSD significantly increased ratings of music excerpts that
were previously rated as personally meaningless or neutral
(Preller et al, 2017). Thus, LSD attributed meaning to
previously meaningless stimuli (Preller et al, 2017).
Autonomic and Adverse Effects
LSD moderately increased blood pressure, heart rate, body
temperature, and pupil size (Dolder et al, 2016; Kaelen et al,
2015; Schmid et al, 2015). The sympathomimetic effects of
100 and 200 μg doses of LSD were similar (Dolder et al, 2016,
2017) and less pronounced than those of MDMA and
stimulants (Hysek et al, 2014b). Acute adverse effects up to
Table 2 Continued
Publications related to
the study
Outcome measures Findings (LSD vs placebo)
Carhart-Harris et al, 2016b Effects after 14 days Increased optimism and trait openness
Kaelen et al, 2016 rsfMRI with/without music
(n= 12)
Interaction of music and LSD on parahipocampal-
visual cortex functional connectivity
Lebedev et al, 2016 rsfMRI with/without music
(n= 12)
Acutely increased entropy predicts trait openness
14 days later
Carhart-Harris et al, 2016c rsfMRI, ASL, MEG (n= 15) Increased blood flow and alpha power in visual
cortex, visual cortex connectivity correlates with
hallucinations, decreased parahippocampus-
retrosplenial cortex connectivity correlates with
ego-dissolution
Roseman et al, 2016 rsfMRI (n= 10) Early visual cortex activity with eyes-closed more
similar to seeing visual inputs
Tagliazucchi et al, 2016 rsfMRI, ego-dissolution Increased global connectivity
Speth et al, 2016 rsfMRI, linguistic references
(n= 15) to mental spaces for
the past, present and future
Fewer mental spaces for the past which were
associated with reduced DMN RSFC (integrity)
Zurich, Switzerland; n= 25; dose: 100 μg p.o.; randomized, double-blind; age: 26 (20–34) years; NCT02451072a, six had previous hallucinogen use
Kraehenmann et al, 2017;
Preller et al, 2017
5D-ASC (n= 22) Ketanserin blocked LSD-induced alterations in
consciousness
Preller et al, 2017 PANAS (n= 22) Greater positive than negative affect; ketanserin
blocked LSD-induced positive affect
Preller et al, 2017 Meaning of music (n= 22) Personally meaningless and neutral music more
meaningful
Preller et al, 2017 BOLD signal to meaningless
(n= 22) vs meaningful music
Increase in medial and lateral frontal brain areas
Study in patients with anxiety with life-threatening disease; Solothurn, Switzerland; n= 12; dose: 200 μg p.o.; randomized, double-blind; age: 50 (39–64) years; NCT00920387a
Gasser et al, 2014 STAI, QLQ-30, SCL-90, HADS
(n= 11)
Significant reduction in STAI-state anxiety at
2 months compared with baseline and beneficial
trend-effects on other outcomes
Liechti et al, 2017 MEQ (n= 11) Induction of mystical-type experiences
Gasser et al, 2015 STAI, interviews (n= 9) Significant reduction in STAI-state and trait anxiety
at 12 months compared with baseline, rise in
reported quality of life
Abbreviations: AMRS, Adjective Mood Rating Scale; ARCI, Addiction Research Center Inventory; ASL, arterial spin labeling; AUC, area under the concentration-time
curve; Cmax, maximal plasma concentration; CIS, creative imagination scale; 5D-ASC, 5 dimensions of altered states of consciousness scale; DMN, default mode network;
FERT, face emotion recognition task; GEMS, Geneva emotional music scale; HADS, hospital anxiety and depression scale; MEG, magnetoencephalography; MEQ,
mystical experience questionnaire; MET, multifaceted empathy test; MIT, mental imagery test; n, number of subjects in the entire study or for whom the respective
outcome was reported; NR, not reported or not registered; PANAS, positive and negative affect scale; PSI, psychotic states inventory; QLQ-30, quality of life
questionnaire 30-item version; RSFC, resting-state functional connectivity; rsfMRI, resting-state functional magnetic brain imaging; SCL-90, symptom check list-90; STAI,
state-trait anxiety inventory; SVO, social value orientation test; Tmax, time to Cmax; t1/2, plasma half-life; VAS, visual analog scale.
aClinicalTrials.gov trial registry number.
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10–24 h after LSD administration included difficulty con-
centrating, headache, dizziness, lack of appetite, dry mouth,
nausea, imbalance, and feeling exhausted. Headaches and
exhaustion may last up to 72 h (Dolder et al, 2016; Schmid
et al, 2015). No severe adverse reactions were reported in
modern LSD studies (Carhart-Harris et al, 2016b; Dolder
et al, 2016; Kaelen et al, 2015; Preller et al, 2017; Schmid et al,
2015). This is consistent with the view that LSD is relatively
safe when used in medical settings and according to safety
guidelines (Johnson et al, 2008). LSD is physically non-toxic,
but there are psychological risks especially when it is used in
unsupervised settings. In addition, it is important to note
that many novel hallucinogens are being used and may even
be sold as LSD but have a different pharmacology and
possibly risk profile than LSD (Rickli et al, 2015, 2016). LSD
has typically been reported to produce flashbacks. Flashbacks
after LSD can be defined as episodic and short (seconds or
minutes) replications of elements of previous substance-
related experiences (Holland and Passie, 2011). In a web-
based survey among hallucinogen users, greater past LSD use
was a predictor of the probability of experiencing unusual
substance-free visual experiences (Baggott et al, 2011).
Clinically significant flashbacks are also defined as halluci-
nogen persisting perception disorder (HPPD). This disorder
is considered rare and occurs almost exclusively in the
context of illicit recreational use or/and in patients with
anxiety disorders and it typically will have a limited course of
months to a year (Halpern and Pope, 1999; Holland and
Passie, 2011; Johnson et al, 2008). In controlled non-
therapeutic research settings, psilocybin did not produce
HPPD or flashbacks (Studerus et al, 2011). However, the
prevalence and relevance of HPPD is unclear and needs to be
studied (Halpern et al, 2016).
Endocrine Effects
LSD acutely increased plasma concentrations of cortisol
(Strajhar et al, 2016), prolactin, oxytocin, and epinephrine
(Schmid et al, 2015). LSD does not increase plasma
concentrations of norepinephrine (Schmid et al, 2015),
testosterone, or progesterone (Strajhar et al, 2016). The
endocrine effects of LSD are consistent with those of other
serotonergic substances including psilocybin, DMT, and
MDMA (Hasler et al, 2004; Hysek et al, 2014b; Seibert et al,
2014; Strassman and Qualls, 1994a).
Model Psychosis
LSD (75 μg, i.v.) increased subjective ratings of cognitive
disorganization and delusional thinking (Carhart-Harris
et al, 2016b). Disordered cognition has been suggested to
be a more fundamental characteristic of LSD’s effects than
positive or negative mood (Carhart-Harris et al, 2016b).
Nevertheless, the LSD experience was not dominated by
unpleasant psychosis-like phenomena but rather character-
ized by an overall positive mood state in the majority of
subjects (Carhart-Harris et al, 2016b). Investigators rated
subjects as more distant from reality and happy after
administration of 200 μg LSD, whereas ratings of anxiety
and paranoid thinking did not increase (Schmid et al, 2015).
Patients with schizophrenia present deficits in sensorimotor
gating, reflected by prepulse inhibition (PPI) of the startle
response. LSD acutely disrupts PPI in both animals
(Halberstadt and Geyer, 2010) and healthy human subjects
(Schmid et al, 2015), producing deficits in information
processing that are similar to those observed in schizo-
phrenia. Similarly, inhibitory processes are impaired in
schizophrenia and in healthy subjects after administration of
LSD (Schmidt et al, 2017).
Emotional Processing
LSD impaired the recognition of sad and fearful faces
(Dolder et al, 2016) and enhanced emotional empathy
(Dolder et al, 2016), similar to psilocybin (Kometer et al,
2012; Preller et al, 2015) and MDMA (Hysek et al, 2014a;
Kuypers et al, 2017). These effects of LSD on emotion
processing may be considered useful in LSD-assisted
psychotherapy. However, LSD also impaired the identifica-
tion of complex emotions (Dolder et al, 2016).
Functional Brain Imaging
LSD acutely decreased the functional integrity of brain
networks (Figure 2a) and the separation between networks
(Carhart-Harris et al, 2016c; Tagliazucchi et al, 2016)
(Figure 2b). At the whole-brain level, LSD increased
functional connectivity between various brain regions
(Figure 3). LSD also increased measures of functional ‘brain
entropy’ (ie, the predictability of resting-state fMRI time
series) across many functional systems (Lebedev et al, 2016).
The acute LSD-induced global increase in ‘brain entropy’ was
associated with trait openness that was assessed 14 days later
(Lebedev et al, 2016). LSD increased thalamocortical resting-
state functional connectivity (RSFC) (Mueller et al, 2017b;
Tagliazucchi et al, 2016), overall connectivity in high-level
cortical regions and the thalamus, and connectivity between
normally more dissociated resting-state networks
(Tagliazucchi et al, 2016). These findings indicate more
globally synchronized activity within the brain and a
reduction of network separation while under the pharmaco-
logical effects of LSD. Similar decreases in within-network
integrity (Carhart-Harris et al, 2014; Muthukumaraswamy
et al, 2013) and increases in between-network connectivity
(Carhart-Harris et al, 2013; Roseman et al, 2014) have been
observed under psilocybin. The LSD-induced increases in
global connectivity, particularly in the temporo-parietal
junction and insular cortex, correlated with feelings of
moderate ‘ego dissolution’ that were produced by LSD
(Tagliazucchi et al, 2016). ‘Ego dissolution’ refers to a
disintegration of the sense of possessing a ‘self’ or identity
that is distinct from others and from the environment
(Preller and Vollenweider, 2016; Tagliazucchi et al, 2016). In
addition, LSD-induced RSFC between the thalamus and right
fusiform gyrus and insula correlated with subjective visual
and auditory alterations, respectively (Mueller et al, 2017b).
Remaining to be determined is the way in which LSD-
induced increases in thalamocortical connectivity may be
linked to the thalamic gating of perceptions (Mueller et al,
2017b). In contrast to the higher connectivity between neural
networks while under the effects of LSD, LSD globally
decreased within-network RSFC (integrity) and within-
network signal variance (Carhart-Harris et al, 2016c)
(Figure 2a). Specifically, LSD decreased default mode
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network (DMN) integrity (Carhart-Harris et al, 2016c) as
previously shown for psilocybin (Carhart-Harris et al, 2014),
and this LSD-induced disintegration of the DMN correlated
with ratings of ego dissolution (Carhart-Harris et al, 2016c;
Tagliazucchi et al, 2016). Furthermore, reductions of RSFC
in the DMN (ie, DMN disintegration) were associated with
fewer mental spaces for the past (ie, decreased mental time
travel to the past) while under the effects of LSD (Speth et al,
2016). Increases in DMN RSFC have been described in
depression, and decreases in DMN RSFC that are induced by
LSD may be linked to its potential antidepressant effects
(Carhart-Harris et al, 2016a).
Arterial spin labeling analyses revealed greater cerebral
blood flow in the visual cortex that was induced by LSD, and
this increase was associated with ratings of complex imagery
on the 5D-ASC (Carhart-Harris et al, 2016c). LSD also
strongly increased RSFC between the primary visual cortex
(V1) and cortical and subcortical brain regions, and this
effect correlated with 5D-ASC ratings of elementary or
complex hallucinations (Carhart-Harris et al, 2016c). Greatly
expanded V1 functional connectivity that is induced by LSD
may indicate that a greater proportion of the brain processes
visual information than under normal conditions (Carhart-
Harris et al, 2016c). Further analyses found that LSD
administration altered eyes-closed spontaneous activity
within retinotopically organized patches of the V1 and
neighboring visual regions (V3), similar to visual stimulation
(Roseman et al, 2016). Thus, the primary visual system is
altered by LSD and behaves as if it perceives spatially
localized visual information when in fact there is none
(Roseman et al, 2016), which is consistent with the notion of
‘seeing with the eyes shut’ (Carhart-Harris et al, 2016c;
Roseman et al, 2016).
LSD-induced decreases in RSFC between the parahippo-
campus and the rest of the brain (particularly the retro-
splenial and posterior cingulate cortex) correlated with VAS
ratings of ego dissolution and altered meaning on the 5D-
ASC (Carhart-Harris et al, 2016c). Similarly, psilocybin
altered activity in parahippocampal-retrosplenial cortex
circuit measured with EEG and this effect correlated with
spirituality and insigthfulness ratings on the 5D-ASC
(Kometer et al, 2015). LSD increased blood oxygen-level-
dependent activity of the supplementary motor area and
prefrontal cortex in response to music without personal
meaning or relevance compared with personally meaningful
and neutral music, indicating enhanced activity in brain
areas that are involved in self-referential cognition and
processing (Preller et al, 2017). LSD reduced left amygdala
reactivity to the presentation of fearful faces (Mueller et al,
2017a). Psilocybin similarly decreased amygdala reactivity to
negative facial expressions (Kraehenmann et al, 2015).
Lower fear perception (Dolder et al, 2016) and amygdala
reactivity may be useful during psychotherapy. Magnetoen-
cephalography showed that LSD decreased oscillatory power
throughout the brain during eyes-closed rest (Carhart-Harris
et al, 2016c) as similarly shown for psilocybin (Kometer et al,
Figure 1 Effects of LSD on the 5D-ASC scale. The data are derived from three studies using doses of 75 μg i.v. (Carhart-Harris et al, 2016b), 100 μg p.o.
(Liechti et al, 2017), and 200 μg p.o. (Schmid et al, 2015) LSD in healthy subjects. LSD predominantly increased ratings in subscales of the dimensions oceanic
boundlessness and visionary restructuralization. LSD-induced increases in subscales of the anxious ego-dissolution dimension and in particular in the anxiety
scale were relatively small. LSD-induced changes on the 5D-ASC scale were significant compared with placebo for all LSD doses and all of the scales, with the
exception of the effects of the 200 μg dose on anxiety. There were no statistical differences in the effects of the intravenous 75 μg (Carhart-Harris et al,
2016b) and oral 100 μg (Liechti et al, 2017) dose of LSD on 5D-ASC scale ratings (data provided by the authors). At 200 μg, LSD produced significant and
relevantly higher ratings of blissful state, insightfulness, and changed meaning of percepts compared with 100 μg. The data are expressed as the mean in 24, 16,
and 20 subjects for the 100 μg, 200 μg, and 75 μg doses of LSD, respectively.
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2015; Muthukumaraswamy et al, 2013) and ayahuasca (Riba
et al, 2002). After LSD administration, lower alpha power
correlated with subjective ratings of simple hallucinations
(Carhart-Harris et al, 2016c). Lower alpha power in occipital
sensors correlated with increases in primary visual cortex
RSFC (Carhart-Harris et al, 2016c). Modern positron
emission tomography (PET) and single-photon emission
computed tomography studies of LSD have not yet been
Figure 2 (a) Mean percentage differences (+SEM) in CBF (red), integrity (blue), and signal variance (green) in 12 different resting-state networks (RSNs)
under LSD relative to placebo (red asterisks indicate statistical significance, *Po0.05; **Po0.01, Bonferroni corrected). (b) Differences in between-RSN RSFC
or RSN ‘segregation’ under LSD vs placebo. Each square in the matrix represents the strength of functional connectivity (positive= red, negative= blue)
between a pair of different RSNs (parameter estimate values). The matrix on the far right displays the between-condition differences in covariance (t values):
red= reduced segregation and blue= increased segregation under LSD. White asterisks represent significant differences (Po0.05, FDR corrected; n= 15).
Reproduced from Carhart-Harris et al (2016c).
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conducted. Other 5-HT hallucinogens, such as psilocybin,
ayahuasca, and mescaline, increased metabolic indices in
frontal brain areas Hallucinogen-induced hyperfrontality is
hypothesized to reflect increased frontal activity due to
flooding with information (Geyer and Vollenweider, 2008;
Vollenweider et al, 1997). In contrast, in an fMRI study,
psilocybin decreased blood flow and BOLD signal in the
thalamus, anterior cingulate, medial prefrontal, and cingulate
cortices (Carhart-Harris et al, 2012). It is not yet clear what
the different imaging modalities represent and how these
inconsistencies can be explained. It has been proposed that
the PET study findings of hyperfrontality reflect the
increased neuronal firing activity while fMRI BOLD
measures correlate with cortical oscillatory activity
(Halberstadt, 2015). Altogether, the first modern imaging
studies of LSD have provided preliminary information on the
neural correlates of altered states of mind that are induced by
LSD. However, there are many limitations. Much data have
been derived from only a few small studies. Chance findings
should be expected especially with regard to the RSFC data.
LSD may also have direct actions on vascular resistance and
blood flow that may confound neuroimaging data. These
preliminary findings need to be confirmed in larger studies
and by different research groups.
Clinical Pharmacology
The pharmacokinetics of LSD have been well investigated
only for oral doses of 100 and 200 μg (Dolder et al, 2015b,
2017; Steuer et al, 2016). LSD concentration-time and
subjective effect-time curves are shown in Figure 4. No data
are available on the concentration-time course of the
Figure 3 Connectome ring showing functional connectivity between 132 regions covering the whole brain. Contrast LSD vs placebo, Po0.05, FDR.
Yellow-red indicates increased functional connectivity, blue indicates decreased connectivity. Figure provided by F Mueller from the Basel fMRI study (Mueller
et al, 2017b).
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intravenous dose of 75 μg LSD that was used in the London
studies. The pharmacokinetics of LSD are dose-proportional,
and elimination kinetics are linear up to 12 h (Dolder et al,
2015b, 2017; Steuer et al, 2016). Maximal plasma concentra-
tions are reached 1.5 h after oral administration (Dolder et al,
2015b, 2017) (Figure 4). The elimination half-life is ~ 3 h
(Dolder et al, 2015b, 2017). LSD can be detected in blood
plasma up to 12–24 h after administration, depending on the
dose (Dolder et al, 2017). 2-Oxo-3-hydroxy-LSD (Oxo-HO-
LSD) is the major metabolite of LSD and is detectable in
urine for a longer time than LSD (Dolder et al, 2015a, b;
Steuer et al, 2016). Oxo-HO-LSD and minor metabolites of
LSD can only be detected at very low concentrations in blood
plasma and serum (o0.3 ng/ml) (Dolder et al, 2015a, b;
Steuer et al, 2016) but are present at higher concentrations in
urine (Dolder et al, 2015a). The intravenous dose of 75 μg
LSD that was used in the London studies likely corresponds
to the oral dose of 100 μg that was used in the Basel and
Zurich studies, based on the comparable effects on the
5D-ASC (Carhart-Harris et al, 2016b; Liechti et al, 2017)
(Figure 1). The subjective, cognitive, and sympathomimetic
effects of oral LSD closely reflected the time course of LSD
concentrations in plasma (Dolder et al, 2015b, 2017)
(Figure 4). Subjective effects of LSD peaked 2.5 h after
administration and lasted for 8 h and 12 h after administra-
tion of 100 μg and 200 μg, respectively (Dolder et al, 2017)
(Figure 4). After intravenous administration of 75 μg LSD,
subjective effects peaked at 45–120 min and lasted 7–8 h
(Carhart-Harris et al, 2016b, c; Kaelen et al, 2015). After a
single dose of LSD, the pharmacodynamic effects lasted as
long as LSD was present in the body, with no evidence of
acute tolerance to the effects of LSD (Dolder et al, 2017).
Tolerance has been reported with repeated daily LSD
administration over 3–7 days (Belleville et al, 1956).
Mid- and Long-Term Effects
In comparison to other illicit substances, epidemiological
studies indicate that the use of classic hallucinogens is
associated with lower psychological distress, lower suicid-
ality, and lower mental health problems (Hendricks et al,
2015). Long-lasting positive effects were documented in
modern studies after controlled administration of psilocybin
(Griffiths et al, 2011; MacLean et al, 2011) and ayahuasca
(Bouso et al, 2012) but have not yet been reported in modern
experimental laboratory studies of LSD. Controlled admin-
istration of LSD in healthy subjects increased optimism and
trait openness 2 weeks after administration and produced
trends toward decreases in distress and delusional thinking
(Carhart-Harris et al, 2016b). In addition, the greatest
increases in openness were observed in subjects who
presented both the highest acute LSD-induced enhancements
of ego dissolution during music listening and greater brain
entropy in frontal areas (Lebedev et al, 2016). However, the
reported increases in optimism and personality trait open-
ness 14 days after LSD administration were observed in
subjects with on average already 14 previous uses of LSD
(Carhart-Harris et al, 2016b; Lebedev et al, 2016) raising the
question of how open and optimistic participants can
actually become or whether these effects are rather transient.
STUDIES IN PATIENTS
Early studies from the 1950s to 1970s indicated that LSD may
have antidepressive and anxiolytic properties (Dos Santos
et al, 2016; Passie et al, 2008; Rucker et al, 2016). LSD-
assisted psychotherapy was often performed in patients with
anxiety and cancer (Pahnke et al, 1969; Sheehan, 1972) and
in patients with depression or related disorders (Rucker et al,
2016). These early practices and studies were relatively
poorly documented methodologically, and replication in
modern studies is needed. Single or few doses of LSD also
reportedly lessened cluster headache and induced remission
more effectively than conventional medications (Schindler
et al, 2015). However, no controlled studies have been
conducted. LSD was also well studied as treatment for
alcohol use disorder (Krebs and Johansen, 2012). LSD and
other hallucinogens are misused but are not addictive
substances leading to compulsive drug taking, withdrawal
or self-administration in animals (Fantegrossi et al, 2008;
Nichols, 2004). Recent trials investigated psilocybin in
patients with alcohol and nicotine use disorder
Figure 4 Pharmacokinetics and pharmacodynamics of LSD. LSD
concentration-time (a) and subjective effect-time (b) curves. LSD was
administered at a dose of 100 and 200 μg p.o. to 24 and 16 healthy subjects,
respectively, at the time point t= 0. Subjective LSD effects (‘any subjective
drug effects’) were assessed repeatedly using VASs (0–100%) along with
blood samples to determine plasma concentrations of LSD (Dolder et al,
2015b; Dolder et al, 2016; Dolder et al, 2017). The LSD concentration
curves (a) represent the mean± SEM of the individual curves fitted to the
observed data using a 1-compartment model. The subjective drug effect
curves (b) represent the mean± SEM of the individual curves fitted to the
observed data using a sigmoidal Emax model linked to the predicted
concentrations (Dolder et al, 2017).
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(Bogenschutz et al, 2015; Johnson et al, 2014), major
depression, and anxiety (Carhart-Harris et al, 2016a;
Griffiths et al, 2016; Grob et al, 2011; Ross et al, 2016).
However, in the past 40 years, no studies of LSD have been
conducted in humans until very recently, and only one
modern trial evaluated LSD in patients (Gasser et al, 2014,
2015) (Table 2). The trial assessed the effects of LSD-assisted
psychotherapy on anxiety in 11 patients with life-threatening
diseases (eight with cancer). Eight patients received 200 μg
LSD twice, and three patients received active placebo (a low
dose of 20 μg LSD) twice in two sessions 2–3 weeks apart,
with an open-label crossover to 200 μg LSD after the first
randomized double-blind treatment phase. At study entry, all
of the patients presented higher ratings of anxiety on the
state-trait anxiety inventory (STAI), six were diagnosed with
generalized anxiety disorder, and seven were diagnosed with
major depression. The study found a significant decrease in
STAI anxiety 2 months after the two LSD sessions compared
with baseline anxiety scores. STAI scores did not decrease in
the placebo group. However, the placebo control group was
too small for statistical comparisons with the treatment
group and therefore a valid control was missing. The study
also found non-significant decreases in depression and
increases in quality of life (Gasser et al, 2014). A follow-up
study at 12 months in nine patients reported sustained
decreases in anxiety, an increase in quality of life, and no
lasting adverse reactions after LSD, but the follow-up lacked a
control group (Gasser et al, 2015). No drug-related severe
adverse effects were reported, with no panic reactions or
other medical or psychiatric complications. Prolonged
psychotic reactions were reportedly rare in patients who
received LSD during psychotherapy (Passie et al, 2008).
Because the therapist used effective existential and meaning-
based psychotherapeutic methods in both the treatment and
control groups, the possible added benefits of LSD are not yet
known. In addition, different and mostly non-evidence-based
therapies have been used in psychedelic-assisted therapy trials
making comparisons between studies difficult. A larger trial
that uses LSD in patients who suffer from anxiety associated
with severe somatic disease and anxiety disorder is conducted
in Switzerland (NCT03153579). In addition, two high-quality
studies recently reported the efficacy of psilocybin in the
treatment of anxiety and depression associated with life-
threatening cancer (Griffiths et al, 2016; Ross et al, 2016).
FUTURE DIRECTIONS
New areas of research on hallucinogens, including LSD, have
just recently opened, and many questions remain unan-
swered. With regard to potential therapeutic long-term
effects of single-dose hallucinogen administration, unclear
is whether these effects depend on a direct pharmacological
action or on the acute psychological response. Differential
indications might be associated with different aspects of
mechanisms of action. Novel dose–response studies of the
acute effects of LSD are lacking, and direct comparisons with
psilocybin need to be made. Neuroimaging studies may help
determine whether long-term changes in mood can be linked
to changes in brain activity and how such patterns change
before, during, and after the acute effects of LSD and other
hallucinogens. The dissociable effects of the substance itself
and psychotherapy on outcomes also need to be elucidated,
in addition to their interactive effects. Larger studies need to
validly define the benefits of using hallucinogens as an
adjunct to psychotherapy and the patient characteristics that
may predict such additional benefits of hallucinogens.
Unclear are the aspects of the acute response to hallucino-
gens that best predict good long-term therapeutic outcomes.
Acute mystical-type effects of psilocybin have been asso-
ciated with greater reductions of anxiety and depression in
patients (Garcia-Romeu et al, 2015; Griffiths et al, 2016; Ross
et al, 2016). This association, however, may not imply
causation. Other aspects of the acute peak response to
hallucinogens could be equally important (Dolder et al, 2016;
Liechti et al, 2017). Many practical aspects of clinical trials
that evaluate the effects of LSD also need to be resolved.
Clinical studies have generally become extremely costly
because of overregulation. This is especially problematic for
LSD research because industry funding is unlikely. In many
countries, the scheduling of LSD still impedes or prohibits
clinical research.
The mechanism of the therapeutic actions of LSD is
unclear. The acute psychedelic or mystical peak experience
characterized by a loss of usual sense of self, sense of unity,
transcendence of time and space, and feelings of positive
mood, awe, and meaning (Pahnke et al, 1970) may
restructure patients’ emotional trust, situational understand-
ing, habits, and views (Gasser et al, 2015). Lower RSFC in the
DMN may be linked to lower rumination and depression
(Carhart-Harris et al, 2016c). Enhanced neurogenesis may be
associated with antidepressant effects. Acutely reduced fear
recognition and amygdala reactivity may facilitate the
processing of negative information (Dolder et al, 2016;
Mueller et al, 2017a), and feelings of closeness and trust
enhance the patient–therapist relationship (Dolder et al,
2016; Schmid et al, 2015). Irrespective of the mechanism, if
LSD in only a few doses may indeed improve health, this
novel treatment paradigm needs to be studied further in
modern clinical studies.
CONCLUSIONS
A few single administrations of LSD or related substances
within a therapeutic setting may be beneficial for patients
with anxiety associated with severe illness, depression, or
addiction. These old–new treatments may have a potential in
psychiatry. As professionals, we should actively study these
new options so patients who are in need will not look
elsewhere for unproven treatments from unregulated
sources. More methodologically sound research on the
psychological and biological mechanisms and therapeutic
potential of LSD in psychiatry is needed.
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